REGN

Regeneron Pharmaceuticals
D

REGN

Arincen73/100B
904.38
USD
1.56
(0.17%)
Pre Open·910.20USD+5.82(+0.64%)
Last updated: · Delayed 15 min
Fair value814.64Plus+11%346Price 904.381,431
Q4 FY2026 · Earnings report
EPS estimate 25.39Revenue estimate 5.85B
OverviewFinancialsForecastEarningsDividendsCompany

Regeneron Pharmaceuticals debt to equity ratio

Regeneron Pharmaceuticals's debt to equity ratio is 0.08: total debt of 2.71B USD against shareholders' equity of 33.50B USD.

Today
0.08
Average, 5 years
0.10
Low, 5 years
0.06
High, 5 years
0.14

Debt to equity = total debt ÷ shareholders' equity = 2.71B ÷ 33.50B = 0.08

Debt to equity
Total debt
Shareholders' equity

Total debt over shareholders' equity at each quarter end.

Debt to equity by year and by quarter

Fiscal yearPeriod endingDebt to equityTotal debtShareholders' equity
Today0.082.71B33.50B
FY202531 Dec 20250.092.71B31.26B
FY202431 Dec 20240.092.70B29.35B
FY202331 Dec 20230.102.70B25.97B
FY202231 Dec 20220.122.70B22.66B
FY202131 Dec 20210.142.70B18.77B
FY202031 Dec 20200.242.70B11.03B
FY201931 Dec 20190.06713.90M11.09B
FY201831 Dec 20180.08708.50M8.76B
FY201731 Dec 20170.11703.45M6.14B
FY201631 Dec 20160.11481.13M4.45B
FY201531 Dec 20150.10375.51M3.65B
FY201431 Dec 20140.18459.06M2.54B
FY201331 Dec 20130.26505.51M1.95B
FY201231 Dec 20120.37457.33M1.25B
FY201131 Dec 20110.90435.53M485.73M
FY201031 Dec 20100.30160.03M527.82M
FY200931 Dec 20090.27109.02M396.76M
FY200831 Dec 20080.015.09M418.85M
FY200731 Dec 20070.44202.29M460.27M
FY200631 Dec 20060.92200.00M216.62M
FY200531 Dec 20051.75200.00M114.00M
FY200431 Dec 20041.10200.00M182.54M
FY200331 Dec 20031.55213.82M137.64M
FY200231 Dec 20021.37200.15M145.98M
FY200131 Dec 20010.75200.58M266.36M
FY200031 Dec 20000.012.68M182.13M
FY199931 Dec 19990.044.10M109.50M
FY199831 Dec 19980.034.20M131.20M
FY199731 Dec 19970.045.60M138.90M
FY199631 Dec 19960.088.70M106.90M
FY199531 Dec 19950.149.50M67.90M
FY199431 Dec 19940.1812.30M67.10M
FY199331 Dec 19930.087.50M98.40M
FY199231 Dec 19920.086.80M87.20M
FY199131 Dec 19910.032.80M106.20M
FY199031 Dec 19900.000.0012.20M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,ROE (return on equity),Current ratio,All ratios

Common questions about Regeneron Pharmaceuticals's debt to equity

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.